When the eye’s drainage system clogs, intraocular pressure (IOP) builds up and causes damage. The pressure can lead to glaucoma and vision loss. Researchers headed by a team at Duke University School ...

How could relapse in leukemia after CAR T treatment—a problem that still affects between 30–60% of patients—be prevented? One major driver is antigen escape: leukemia cells can dial down or lose the ...

In intensified bioprocessing, the engineered CHO host supports higher titers and long culture duration in continuous perfusion.

Over the past decade, however, a wave of technological advances has begun to expand the druggable proteome. These include covalent inhibitors (such as sotorasib), chemical proteomics, and AI-enabled ...

Therapeutic developers are increasingly rebuilding their workflows around AI to bring drugs to patients faster.

With clinical data beginning to emerge, big pharma is signaling its belief that in vivo CAR generation is the next immunotherapy breakthrough.

Non-CHO cell expression systems gain traction as faster, more flexible alternatives for biologics manufacturing.

As climate pressure mounts, new platforms tackle delivery, regulation, trait stacking, and data bottlenecks limiting agricultural genome editing.

Enzene’s New Jersey facility offers efficient, fully continuous or hybrid vat production within a modular framework.

I have always been a bit of a skeptic about how important AI will be for the biotechnology industry, but, given a few […] ...

Cas9, Transcription Activator-Like Effector Nucleases (TALENs), and Zinc-Finger nucleases (ZFNs) have demonstrated great utility, primarily for genetic knock-out applications, none have been adopted ...